5 Key Takeaways

• 1

  A blood test measuring phosphorylated tau217 can predict the onset of symptomatic Alzheimer's disease years in advance.

• 2

  Researchers developed statistical models using plasma p-tau217 levels to estimate the timing of cognitive symptom onset.

• 3

  The study indicates that p-tau217 levels rise progressively during the preclinical phase of Alzheimer's.

• 4

  P-tau217 clocks demonstrated predictive performance across diverse populations and correlated with established Alzheimer's markers.

• 5

  The blood test offers a cheaper and more accessible alternative to PET scans and spinal fluid tests for Alzheimer's prediction.